Podcasts about life sciences

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As the Japanese police prepare for a raid on the Aum Shinrikyo compound, cult leader Shoko Asahara launches a desperate chemical weapons attack in downtown Tokyo. During the height of Monday morning rush hour, Aum terrorists target five commuter trains with sarin gas, killing 13 people and scarring the psyche of an entire nation. In the aftermath, survivors struggle to pick up the pieces of their lives and adapt to new realities.    SOURCES: Amarasingam, A. (2017, April 5). A history of sarin as a weapon. The Atlantic.  Brackett, D. W. Holy Terror: Armageddon in Tokyo. 1996. Cotton, Simon. “Nerve Agents: What Are They and How Do They Work?” American Scientist, vol. 106, no. 3, 2018, pp. 138–40.  Danzig, Richard; Sageman, Marc; Leighton, Terrance; Hough, Lloyd; Yuki, Hidemi; Kotani, Rui; Hosford, Zachary M.. Aum Shinrikyo: Insights Into How Terrorists Develop Biological and Chemical Weapons . Center for a New American Security. 2011 “Former ER Doctor Recalls Fear Treating Victims in 1995 Tokyo Sarin Attack.” The Japan Times, March 18, 2025.. Gunaratna, Rohan. “Aum Shinrikyo's Rise, Fall and Revival.” Counter Terrorist Trends and Analyses, vol. 10, no. 8, 2018, pp. 1–6.  Harmon, Christopher C. “How Terrorist Groups End: Studies of the Twentieth Century.” Strategic Studies Quarterly, vol. 4, no. 3, 2010, pp. 43–84. JSTOR, http://www.jstor.org/stable/26269787.  “IHT: A Safe and Sure System — Until Now.” The New York Times, 21 Mar. 1995. Jones, Seth G., and Martin C. Libicki. “Policing and Japan's Aum Shinrikyo.” How Terrorist Groups End: Lessons for Countering al Qa'ida, RAND Corporation, 2008, pp. 45–62.  Kaplan, David E. (1996) “Aum's Shoko Asahara and the Cult at the End of the World”. WIRED.  Lifton, Robert Jay. Destroying the World to Save It: Aum Shinrikyo, Apocalyptic Violence, and the New Global Terrorism. 1999. Murakami, Haruki. Underground: The Tokyo Gas Attack and the Japanese Psyche. Translated by Alfred Birnbaum and Philip Gabriel. 2001. Murphy, P. (2014, June 21). Matsumoto: Aum's sarin guinea pig. The Japan Times.  Reader, Ian. Religious Violence in Contemporary Japan: The Case of Aum Shinrikyo.  2000. Tucker, Jonathan B. “Chemical/Biological Terrorism: Coping with a New Threat.” Politics and the Life Sciences, vol. 15, no. 2, 1996, pp. 167–83.  Ushiyama, Rin. “Shock and Anger: Societal Responses to the Tokyo Subway Attack.” Aum Shinrikyō and Religious Terrorism in Japanese Collective Memory., The British Academy, 2023, pp. 52–80.  Williams, Richard. 2003. “Marathon Man.” The Guardian, May 16, 2003. “Woman bedridden since AUM cult's 1995 sarin gas attack on Tokyo subway dies at 56.” The Mainichi (English), 20 Mar. 2020, “30 Years After Sarin Attack — Lessons Learned / Brother Kept Diary For Sister Caught in Sarin Attack, Chronicling Her 25-Year Struggle With Illness” The Japan News, 19 Mar. 2025, Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, host Sandy Vance sits down with Dr. Zayed Yasin, MD, Global Head of Healthcare and Life Sciences at Writer, for a thoughtful and practical conversation about what AI really means for healthcare today. Drawing on his background as a clinician, Dr. Yasin shares how AI can eliminate the “boring” aspects of the job, allowing teams to focus on what matters most: patients and outcomes. Together, they delve into building effective clinical programs in value-based care, leveraging AI for payers, exploring real-world case studies, and examining why many organizations struggle with implementation. If you're curious about where AI is delivering real ROI right now (and why the best way to learn is to lean in and start working), this episode is for you.In this episode, they talk about:Dr. Yasin's background as a clinician and his interest in AI AI will help people focus on what's really important while taking away the boring parts of the jobBuilding the clinical program at a value-based care organizationHow to make these programs work for payersWriter case studies using this technologyWhy organizations struggle with implementing AIFuture big use cases in AILean in hard; you don't start learning until you start working ROI can be attained quickly in places with very little riskUnless you're an AI company, you're not an AI companyA Little About Dr. Yasin:Dr. Yasin runs the Healthcare and Life Sciences group at Writer, the end-to-end platform for enterprises scaling AI. After leaving academic emergency medicine, he built telemedicine and VBC businesses before leading Writer's HCLS AI transformation efforts.

The market is mispricing the human brain. Some Investors view Brain-Computer Interfaces (BCI) and other neurotech as the next iteration of the medical device, a slightly better stent or a more advanced catheter. This is a category error. As Matt Angle (Paradromics) and Connor Glass (Phantom Neuro) articulate its not a product, its the next modem.The parallel is the internet in 1993. We are moving from a low-bandwidth, text-based era of biology into a streaming, high-fidelity era. This shift requires a convergence of disciplines, Material science, analog engineering, and machine learning, mirroring the semiconductor boom of the 1960s. Austin, with its unique trinity of industrial scale, software speed, and risk-tolerance, has emerged as the global command center for this revolutionThe Agenda:0:00 - Intro 02:48 - Electrical Input and Output of the Body 08:13 - Navigating the Valley of Death via DARPA 16:54 - Moral Hazard of Regulatory Caution 23:45 - BCI as the Next Internet 37:51 - Capital Stack and the Platform Shift 50:31 - Declaring Austin the Global Neurotech Capital 55:23 - Convergence of Semiconductor DisciplinesGuest LinksMatt Angle: LinkedIn, Paradromics (Website, X, LinkedIn)Connor Glass: LinkedIn, Phantom Neuro (Website, X, LinkedIn) -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

Daniel Garza had momentum. Acting roles, directing gigs, national tours lined up. Then anal cancer stopped everything. Radiation wrecked his body, stripped him of control, and left him in diapers, staring down despair. His partner, Christian Ramirez, carried him through the darkest nights, changed his wounds, fought hospitals, and paid the price with his own health. Christian still lives with permanent damage from caregiving, but he stayed anyway.Together they talk with me about masculinity, sex, shame, friendship, and survival. They describe the friendships that vanished, the laughter that kept them alive, and the brutal reality of caregiving no one prepares you for. We get into survivor guilt, PTSD, and why even rocks need rocks. Daniel is now an actor, director, and comedian living with HIV. Christian continues to tell the unfiltered truth about what it takes to be a caregiver and stay whole. This episode gives voice to both sides of the cancer experience, the survivor and the one who stands guard. RELATED LINKSDaniel Garza IMDbDaniel Garza on InstagramDaniel Garza on FacebookChristian Ramirez on LinkedInLilmesican Productions Inc (Daniel & Christian)Stupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm's Investigations + White Collar Defense Group, hosted the twelfth episode of When Your Life Sciences Are on the Line, where leading practitioners and thought leaders share the insights and advice needed to manage business and legal risk in the life sciences sector. In this episode, Kate and Nate speak with Brigid Bondoc, partner and leader of Morrison Foerster's U.S. Food and Drug Administration (FDA) & Healthcare Regulatory and Compliance Group. Together, they discuss the evolving role of artificial intelligence (AI) within the FDA and its implications for the life sciences industry. They address how the FDA is beginning to integrate AI tools like “Elsa” to improve efficiency in inspections, data analysis, and safety monitoring. Brigid also explores key regulatory and compliance challenges surrounding AI-driven clinical decision support software, emphasizing the importance of explainability and human oversight. The conversation closes with an examination of the FDA's new approach to releasing complete response letters, and how this increased transparency may reshape industry strategies for engagement with the agency.

As artificial intelligence continues to dominate conversations across life sciences, many companies are reaching an inflection point between experimentation and real-world impact. In a recent episode of The Top Line, Mark Sullivan, president of regulated industries at Salesforce, said the industry is moving past broad promises toward a clearer divide between organizations that have laid the groundwork for AI and those still struggling to operationalize it. While early pilots have delivered mixed results, Sullivan said the next phase will be defined by how effectively companies use AI to augment their workforce, not replace it. Much like laptops or smartphones, AI proficiency is quickly becoming a baseline expectation for professionals, shaping productivity, decision-making and resilience across drug development, manufacturing and commercialization. Sullivan emphasized that success with AI agents hinges on trust, governance and high-quality data—particularly in an industry where accuracy and compliance are nonnegotiable. Life sciences organizations are beginning to see value in agents that support patient engagement, clinical trial matching and commercial execution, but only when those agents are grounded in enterprise data and clear guardrails. With as much as 80% of industry data unstructured, he said, the process of deploying agents often exposes deeper data and architecture challenges that must be addressed. Companies that solve for these issues can unlock both efficiency and growth, using AI not just to cut costs, but to strengthen patient relationships and drive innovation. The conversation offers a practical look at how life sciences leaders can move beyond the hype and build an agentic strategy that delivers measurable results—making it a must-listen for anyone navigating AI adoption in a regulated environment.See omnystudio.com/listener for privacy information.

We love to hear from our listeners. Send us a message.We're sharing this Better Biopharma episode on Cell & Gene: The Podcast because Better Biopharma is a sister show in the Life Science Connect family, and this conversation touches so many of the same challenges, pressures, and big-picture shifts our audience is thinking about right now. CGT doesn't live in a bubble, and neither do the people building it. So we wanted to bring this wider, cross-industry conversation straight to you.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

In this episode of Disruption/Interruption, host KJ sits down with Jurek Kozyra, founder and CEO of Nanovery, to explore how DNA nanotechnology and AI are revolutionizing molecular medicine. Discover how tiny nanorobots made from DNA could dramatically accelerate drug development, make diagnostics faster and more affordable, and potentially cure diseases that were previously untreatable. From detecting diseases in hours instead of days to cutting years off the drug development process, this conversation reveals the cutting-edge science that's transforming healthcare. Four Key Takeaways: The Promise of Oligonucleotide Therapeutics (9:06) Traditional medicine targets defective proteins, but many diseases can't be cured because we can't find the right molecule. Oligonucleotide therapeutics target mRNA—the underlying mechanism of disease—meaning you could potentially cure all diseases since all proteins come from mRNA. DNA Nanorobots for Rapid Detection (14:12) Nanovery's DNA nanorobots can detect diseases in blood samples within 2-4 hours compared to traditional lab tests that take two days. These self-assembling machines produce fluorescent signals when they find specific DNA or RNA molecules, enabling point-of-care diagnostics. Accelerating Drug Development (17:13) Pharmaceutical companies race against 20-year patents while drugs take 10+ years to develop. Nanovery's technology provides more accurate data at lower cost and time, potentially shaving years off the development process and helping more drugs successfully reach the market. Real-World Clinical Validation (20:26) In a hospital study with 170 patient samples, Nanovery's technology delivered same or better results than traditional tests in just two hours instead of two days—a game-changer for emergency situations like drug overdoses where immediate answers are critical. Quote of the Show (9:05):"If you can target mRNA very specifically, that means that in theory you could potentially cure all diseases. That's why this area is so exciting right now." – Jurek Kozyra Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jurek Kozyra: LinkedIn: https://www.linkedin.com/in/j3ny/ Company Website: https://nanovery.co.uk How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com AI is finally mature enough to move out of the way so nurses and clinicians can put humans back at the center of care.  In this episode, Mary Varghese Presti, Corporate Vice President of Microsoft Health and Life Sciences, discusses how global clinician shortages and rising acuity are colliding with an “AI frontier” that can reshape documentation, workflows, and patient outcomes. She shares her personal story as the daughter and former nurse who saw workforce gaps firsthand, then explains why Dragon Copilot for nurses was built to relieve documentation overload and capture the “invisible” work nurses do at the bedside. Mary breaks down the leap from copilots to agentic services, where digital colleagues take on predictable, nonclinical tasks and surface patterns clinicians would miss, as in Stanford's AI-enabled tumor boards. Finally, she paints a future of hybrid human–digital teams and ambient, background technology that restores time, presence, and dignity to care.  Tune in and learn how AI can truly serve caregivers! Resources Connect with and follow Mary Varghese Presti on LinkedIn. Follow Microsoft on LinkedIn. Visit the Microsoft and Life Sciences website! Listen to Mary's previous interview on our podcast here. Watch Mary's keynote presentation at the HLTH conference here.

Trevor Maxwell lived the archetype of masculinity in rural Maine. Big, strong, splitting wood, raising kids, and carrying the load. Then cancer ripped that script apart. In 2018 he was bedridden, emasculated, ashamed, and convinced his family would be better off without him. His wife refused to let him disappear. That moment forced Trevor to face his depression, get help, and rebuild himself. Out of that came Man Up To Cancer, now the largest community for men with cancer, a place where men stop pretending they are bulletproof and start being honest with each other.Eric Charsky joins the conversation. A veteran with five cancers, forty-nine surgeries, and the scars to prove it, Eric lays out what happens when the military's invincible mindset collides with mortality. Together, we talk masculinity, vulnerability, sex, shame, and survival. This episode is blunt, raw, and overdue.RELATED LINKSMan Up To CancerTrevor Maxwell on LinkedInDempsey CenterEric Charsky on LinkedInStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry trends, new developments, and policy surprises from their respective coverage areas. Topics include biotech funding dynamics, FDA leadership, China's growing role, favorite holiday movies, and much, much more. Special thanks to Tyler Menichiello and the Better Biopharma podcast for hosting this roundtable discussion. Happy New Year!     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.

Judith Waltz, Partner, Foley & Lardner LLP, Faraz Siddiqui, Assistant General Counsel, Memorial Sloan Kettering Cancer Center, David Lazarus, Partner, Foley Hoag LLP, and John Hood, Associate, Akerman LLP, discuss some of the key health law developments from 2025 and what to expect in 2026. They cover a wide range of legislative, regulatory, and judicial issues, focusing on Medicare and Medicaid, public health, civil and criminal enforcement, and drug development. Waltz, Siddiqui, Lazarus, and Hood are editors of AHLA's bestselling title, Federal Health Care Laws and Regulations.Watch this episode: https://www.youtube.com/watch?v=9H7hOIesrDALearn more about AHLA's Federal Health Laws and Regulations: https://store.lexisnexis.com/ahla/products/ahla-federal-health-care-laws-and-regulations-ahla-members-grpussku5626742m.html Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

In this episode of Tiny Show and Tell Us, we kick things off with a quick shout-out to a listener who started flossing thanks to a previous episode. Then we dive into the hidden history of the women “computers” at Harvard Observatory, including Henrietta Leavitt, who laid the foundation for modern astronomy with her groundbreaking discoveries including calculating the size of the Milky Way. Then we discuss the co-evolutionary arms race between passion vines and Heliconius butterflies, which includes fake eggs, toxic fruit, and impaled caterpillars.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mia Horowitz, PhD, Tel Aviv University; Aitor Aguirre, PhD, Michigan State University, Michigan, USA; and Ying Sun, PhD, University of Cincinnati, discuss the use of organoid models in lysosomal disorder research and drug development.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session3-organoids-and-lab-grown-models-in-lysosomal-disorders/Learning ObjectivesDescribe the use of heart organoid models to better understand the pathophysiology of lysosomal disorders and its clinical relevanceDescribe the use and application of brain organoid models in neuropathic Gaucher disease research and treatmentFacultyMia Horowitz, PhD, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University.Aitor Aguirre, PhD, Associate Professor of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Chief, Division of Developmental and Stem Cell Biology (IQ), Director, MSU Stem Cell Core, Michigan State University.Ying Sun, PhD, Professor, Cincinnati Children's Hospital Medical Center, University of Cincinnati.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Mia Horowitz, PhDDr. Horowitz has no relevant financial relationships to disclose.Aitor Aguirre, PhDDr. Aguirre has no relevant financial relationships to disclose.Ying Sun, PhDDr. Sun receives research support from Enkefalos Biosciences and Yuhan Corporation.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode from the archives Tammy sits down with Keena Patel-Moran, the Healthcare and Lifesciences Industry Lead at Launch by NTT DATA. Keena and Tammy discuss ways to improve the industry and give patients the support they need and deserve. They discuss why doctors should look beyond just symptoms and make a case that improving healthcare processes is not only better for patients and care-takers but is also good for business. Please note that the views expressed may not necessarily be those of NTT DATALinks: Keena Patel-MoranLearn more about Launch by NTT DATASee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Breakthrough science has never been stronger — yet patients still miss life-saving therapies.Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery.The problem isn't discovery. It's how science, capital, and systems are aligned — or not.Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem.As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up.In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine.

In this milestone 100th episode of Tiny Matters we take you on a personal journey into what first inspired our passion for science. Sam shares the story of her childhood struggle with germophobia and the brain-altering bacteria that kicked it off, likely causing a condition called PANDAS: Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. PANDAS may have led to her OCD, but it also fueled Sam's fascination with the microscopic world, germ theory, and the ways infections can shape our brains. Then Deboki dives into her early fascination with vaccines, inspired by the interests of her scientist parents. She shares the history of the polio vaccine — a story of victory but also tragedy that led to significant progress, both in terms of science and safety.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of the BioTalk with Rich Bendis Podcast brings together leaders from industry, academia, and economic development to unpack the vision behind a new life sciences Innovation District anchored in Prince William County. With introductions to NAUGEN, George Mason University's Institute for Biohealth Innovation, and the Prince William County Department of Economic Development, setting the stage for how each organization contributes to the district's foundation. The guests talk about the life science assets, research strengths, and translational capabilities that define the district and explain why it is positioned to support biotechnology and advanced R&D companies. The conversation explores how the partnership between Prince William County, George Mason University, and the City of Manassas came together, outlining the distinct roles each plays in advancing a shared strategy. The episode also introduces the NISA program, detailing how it supports companies seeking a soft-landing pathway into the district, the types of organizations best suited for the program, and the facilities, talent, and collaborative resources participants can access both immediately and over time. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Jaehan Park is Founder and CEO of NAUGEN, a global innovation accelerator advancing novel technologies across life sciences and deep tech. With more than 25 years of experience in strategy and business development, he has led collaborations spanning cancer immunotherapy, vaccines, and biologics with global pharmaceutical companies and academic institutions. He leads the NISA Program in partnership with George Mason University and serves as a Mentor-in-Residence at KIC DC, supporting international startups entering U.S. markets. Amy Adams is Executive Director of George Mason University's Institute for Biohealth Innovation, where she advances biohealth research and innovation across more than 300 faculty and thousands of students. Her work focuses on partnerships, shared research infrastructure, and building hubs that connect academia with industry. She is co-leading the development of the Innovation District anchored at Mason's SciTech campus and serves on the boards of BioHealth Innovation and the Association of University Research Parks. Christina Winn leads the Prince William County Department of Economic Development, guiding investment, business growth, and redevelopment efforts across one of Virginia's largest counties. She is overseeing the development of a research-driven Innovation District in partnership with George Mason University and the City of Manassas, supported by a GO Virginia grant. Her career includes leading large-scale economic development initiatives that have driven significant capital investment, job creation, and national visibility for the region.

Tune in as Glenn Hunzinger and Roel van den Akker share their outlook for pharmaceutical and life sciences dealmaking in 2026. They discuss improving market conditions, innovation driven growth, and how upcoming loss of exclusivity is shaping deal strategy.  Discussion highlights: Strong innovation, healthy balance sheets, and improving capital markets support a positive outlook for 2026 M&A is expected to remain precision-led and asset-focused, centered on differentiated science and key therapeutic areas Accelerating loss of exclusivity (2026–2029) is increasing reliance on external innovation Mid-sized deals have dominated, but clearer policy and better financing may enable larger strategic transactions As innovation globalizes, companies are sourcing assets more deliberately worldwide, with the US remaining a core life sciences hub Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Roel van den Akker, US Pharmaceutical & Life Sciences Deals Leader, PwCLinked Materials:https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Learn more about The 2030 Project: A Cornell Climate Initiative https://climate.cornell.edu/Cornell College of Engineering https://www.engineering.cornell.edu/Cornell College of Agriculture and Life Sciences https://cals.cornell.edu/As concerns about climate change intensify, researchers are exploring the potential for large-scale human intervention in the Earth's climate system – a set of strategies collectively known as geoengineering. Some of these strategies, called sunlight reflection methods, involve techniques like adding aerosols to the stratosphere to reflect a small portion of solar radiation back into space. Though still in the early stages of research, sunlight reflection and other geoengineering ideas raise complex scientific, ethical, and political questions.In this Keynote, three experts from Cornell University delve into what geoengineering is and what it isn't. Clarifying the science, the panel will separate fact from fiction and discuss why a cautious, transparent, and interdisciplinary approach is essential.This conversation is part of The 2030 Project: A Cornell Climate Initiative, administered by the Cornell Atkinson Center for Sustainability. Follow eCornell on YouTube, Facebook, Instagram, LinkedIn, TikTok, and X.

Darkness Radio Presents: Reincarnation, NDE, AI & Life Sciences and Forbidden Masonry with Historian/Professor/Presenter/Archaeologist/ Podcaster/ Author, Dr. Heather Lynn! On Today's Darkness Radio, while traveling on the road, Dr. Heather Lynn graciously stops by for an intriguing chat about everything from reincarnation and the death process, to AI and life sciences, to favorite holiday traditions and their true roots, to a forbidden branch of Masonry that she is currently doing research on!  WARNING:  This program moves a mile a minute!  and we like it that way! Find out more about Dr. Lynn at her website:   https://www.drheatherlynn.com/ Wanna see those pictures of the Boars Head ceremony that Dr. Lynn was talking about?  Head over here:  https://drheatherlynn.substack.com/ Check out Dr. Lynn's podcast:  https://www.drheatherlynn.com/the-midnight-academy Get Dr. Lynn's Book , "Annunaki Revelation...":  https://bit.ly/4j16hbL Check out Jessica Freeburg's website and get tickets to her events here:  https://jessicafreeburg.com/upcoming-events/ There are new and different (and really cool) items all the time in the Darkness Radio Online store at our website! . check out the Darkness Radio Store!   https://www.darknessradioshow.com/store/ Make sure you update your Darkness Radio Apple Apps! and subscribe to the Darkness Radio You Tube page:  https://www.youtube.com/@DRTimDennis #paranormal  #supernatural  #paranormalpodcasts  #darknessradio  #timdennis  #drheatherlynn  #historian #archaeologist #ancientaliens #coasttocoast  #ghosts  #spirits #hauntings #baphomet #annunaki #annunakirevelation #reincarnation #neardeathexperience #artificialintelligence #AI #freemasons #paranormalinvestigation   #Psychics  #Aliens  #ancientegypt #pyramids #knightstemplar #UFO #UAP #Extraterrestrials  #Alienspaceships #holidaytraditions

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Robert Wenier, Global Head of Cloud and Infrastructure at AstraZeneca. Robert leads enterprise cloud, infrastructure, and platform strategy across a highly regulated, data-intensive global organization. Robert joins Emerj CEO and Head of Research Daniel Faggella to discuss how enterprise data and AI architectures are shifting from service-oriented and microservice models toward emerging agentic architectures that prioritize end-to-end business outcomes over stepwise technical execution. The conversation explores why AI is moving from a supporting role to a direct driver of competitive advantage, and how this changes expectations for infrastructure, data strategy, and leadership ownership. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show! Watch Daniel and Robert's conversation on our new YouTube Channel: youtube.com/@EmerjAIResearch.

About Mary Varghese Presti:Mary Varghese Presti is a transformational healthcare leader with over two decades of experience spanning clinical care, federal reform, biopharma, and health technology. As Corporate Vice President of Microsoft Health & Life Sciences, she drives growth in complex environments by creating clear strategy, aligning organizations, and operationalizing execution with discipline. Her prior roles include leading Nuance's Dragon Medical business, overseeing IBM Watson Health's Life Sciences portfolio, incubating new ventures at athenahealth, and driving digital-health transformation at Pfizer. She began her career as a pediatric nurse at Johns Hopkins and later helped shape national health IT and payment reforms at Booz Allen. Known for navigating complexity with optimism and rigor, she consistently turns ambiguity into strategy and strategy into measurable results.Things You'll Learn:AI in healthcare is evolving from simple assistants to agentic services that can independently execute predictable workflows, allowing clinicians to regain time and focus. This shift enables a hybrid workforce where human and digital colleagues work side by side.Dragon Copilot for nurses was designed specifically to support the way nurses document care, capturing structured inputs such as vitals, intake/output, and observations through natural speech. By reducing EHR time and ambiently recording bedside interactions, it helps turn “caring out loud” into complete documentation.Nurses spend more than a quarter of their 12-hour shifts documenting in the EHR, often feeling emotionally torn between screens and patients. AI that listens in the background can significantly reduce this burden while allowing for more presence at the bedside.New tools are starting to expose the “invisible work” nurses perform, from constant micro-assessments to coordination with ancillary departments. Making this work visible is a critical step toward properly valuing nursing labor and improving workforce planning.Real-world use cases, such as AI agents assembling data for tumor boards at academic centers, show that agentic workflows can compress decision timelines from weeks to days. These same principles can be extended to many clinical and non-clinical tasks, accelerating care while preserving clinician judgment.Resources:Connect with and follow Mary Varghese Presti on LinkedIn.Follow Microsoft on LinkedIn.Visit the Microsoft and Life Sciences website.Listen to Mary's previous interview on our podcast here.Watch Mary's keynote presentation at the HLTH conference here.

Darkness Radio Presents: Reincarnation, NDE, AI & Life Sciences and Forbidden Masonry with Historian/Professor/Presenter/Archaeologist/ Podcaster/ Author, Dr. Heather Lynn! On Today's Darkness Radio, while traveling on the road, Dr. Heather Lynn graciously stops by for an intriguing chat about everything from reincarnation and the death process, to AI and life sciences, to favorite holiday traditions and their true roots, to a forbidden branch of Masonry that she is currently doing research on!  WARNING:  This program moves a mile a minute!  and we like it that way! Find out more about Dr. Lynn at her website:   https://www.drheatherlynn.com/ Wanna see those pictures of the Boars Head ceremony that Dr. Lynn was talking about?  Head over here:  https://drheatherlynn.substack.com/ Check out Dr. Lynn's podcast:  https://www.drheatherlynn.com/the-midnight-academy Get Dr. Lynn's Book , "Annunaki Revelation...":  https://bit.ly/4j16hbL Check out Jessica Freeburg's website and get tickets to her events here:  https://jessicafreeburg.com/upcoming-events/ There are new and different (and really cool) items all the time in the Darkness Radio Online store at our website! . check out the Darkness Radio Store!   https://www.darknessradioshow.com/store/ Make sure you update your Darkness Radio Apple Apps! and subscribe to the Darkness Radio You Tube page:  https://www.youtube.com/@DRTimDennis #paranormal  #supernatural  #paranormalpodcasts  #darknessradio  #timdennis  #drheatherlynn  #historian #archaeologist #ancientaliens #coasttocoast  #ghosts  #spirits #hauntings #baphomet #annunaki #annunakirevelation #reincarnation #neardeathexperience #artificialintelligence #AI #freemasons #paranormalinvestigation   #Psychics  #Aliens  #ancientegypt #pyramids #knightstemplar #UFO #UAP #Extraterrestrials  #Alienspaceships #holidaytraditions

In a new pharmaphorum podcast, guest Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials. The conversation touches upon how large language models (or LLMs) can be gotten into production in regulated spaces – and why generic models won't cut it in this domain – as well as the role of real-world data in quantifying and reducing patient burden. You can listen to episode 233 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

In this episode of Tiny Show and Tell Us, we read an email from “baby sis” aka Binky aka Sam's younger sister Caroline who writes in about an alarming pregnancy test that predates today's at-home tests. Then we talk about a fascinating study that found a dead salmon showed brain activity in an MRI machine. Spoiler: It wasn't actually alive, scientists just really needed to rethink MRI analysis. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode Justin records live at HLTH25 in Las Vegas.This week on the final HLTH25 episode, Justin talks to Rowland Illing, MD, Global Chief Medical Officer and Director at Healthcare and Life Sciences at Amazon Web Services (AWS), and Jonathan Bush, Founder & Chief Executive Officer at Zus Health.

This episode features Olivier Godement, Head of Product for Business Products at OpenAI, discussing the current state and future of AI adoption in enterprises, with a particular focus on the recent releases of GPT 5.1 and Codex. The conversation explores how these models are achieving meaningful automation in specific domains like coding, customer support, and life sciences: where companies like Amgen are using AI to accelerate drug development timelines from months to weeks through automated regulatory documentation. Olivier reveals that while complete job automation remains challenging and requires substantial scaffolding, harnesses, and evaluation frameworks, certain use cases like coding are reaching a tipping point where engineers would "riot" if AI tools were taken away. The discussion covers the importance of cost reduction in unlocking new use cases, the emerging significance of reinforcement fine-tuning (RFT) for frontier customers, and OpenAI's philosophy of providing not just models but reference architectures and harnesses to maximize developer success. (0:00) Intro(1:46) Discussing GPT-5.1(2:57) Adoption and Impact of Codex(4:09) Scientific Community's Use of GPT-5.1(6:37) Challenges in AI Automation(8:19) AI in Life Sciences and Pharma(11:48) Enterprise AI Adoption and Ecosystem(16:04) Future of AI Models and Continuous Learning(24:20) Cost and Efficiency in AI Deployment(27:10) Reinforcement Learning and Enterprise Use Cases(31:17) Key Factors Influencing Model Choice(34:21) Challenges in Model Deployment and Adaptation(38:29) Voice Technology: The Next Frontier(41:08) The Rise of AI in Software Engineering(52:09) Quickfire With your co-hosts: @jacobeffron - Partner at Redpoint, Former PM Flatiron Health @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @jordan_segall - Partner at Redpoint

Not a fan of daylight savings? Beyond the depressingly early sunsets, that may be because it's messing with your circadian clock. In this episode of Tiny Matters, we ask, “How do organisms — from bacteria to sea anemones to humans — keep track of time?” We talk about circadian clocks and how both internal molecular changes and environmental cues called “zeitgebers,” which include things like light and food, synchronize biological rhythms and help all of us survive.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On today's episode, we're changing course a little. Instead of interviewing a life science company leader, we're speaking to someone who empowers them and helps their companies to grow!Elizabeth Chabe is the CEO of High Touch Group, a marketing consultancy firm specializing in life science clients. Her science marketing playbook, The Giant's Ladder, is a #1 bestseller, and her work has been featured in The New York Times, Entrepreneur and CNBC, among others.inquiries@elizabethchabe.com Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In 1975 workers at Life Science Products, a small makeshift pesticide factory in Hopewell, Virginia, became ill after exposure to Kepone, the brand name for the pesticide chlordecone. They made the poison under contract for a much larger Hopewell company, Allied Chemical. Life Science workers had been breathing in the dust for more than a year. Ingestion of the chemical made their bodies seize and shake. News of ill workers eventually led to the discovery of widespread environmental contamination of the nearby James River and the landscape of the small, working-class city. Not only had Life Science dumped the chemical, but so had Allied when the company manufactured it in the 1960s and early 1970s. The resulting toxic impact was not only on the city of Hopewell but also on the faraway fields where Kepone was used as an insecticide.Aspects of this environmental tragedy are all too common: corporate avarice, ignorance, and regulatory failure combined with race and geography to determine toxicity and shape the response. But the Kepone story also contains some surprising medical, legal, and political moments amid the disaster. With Poison Powder: The Kepone Disaster in Virginia and Its Legacy (U Georgia Press, 2023) Gregory S. Wilson explores the conditions that put the Kepone factory and the workers there in the first place and the effects of the poison on the people and natural world long after 1975. Although the manufacture and use of Kepone is now banned by the Environmental Protection Agency, organochlorines have long half-lives, and these toxic compounds and their residues still remain in the environment. Matthew Powell is a doctoral student studying history at the University of Georgia. He focuses on the intersection of environmental and labor history, looking at how workers understand the natural world around them. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

On this episode Justin records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Michael Silverstein, Managing Partner of Healthcare IT & Life Sciences, DRI and Kamal Jethwani, MD, Co-Founder, Decimal.health and VP, Digital Ventures, Moffitt Cancer Center. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Meet Breanne Buehl, Head of Healthcare & Life Sciences at Broadcom. They discuss how private and hybrid cloud strategies are transforming healthcare's digital infrastructure. They explore thought leadership topics including: 1. AI + Genomics Infrastructure: balancing innovation with compliance and cost. 2. Reducing Clinician Burnout: tech as a force multiplier, not a friction point. 3. Health Equity by Design: enabling access through scalable infrastructure. 5. Digital Transformation in Life Sciences: from discovery to delivery. From managing sensitive patient data and ensuring regulatory compliance to integrating generative AI for predictive analytics and precision medicine, Buehl explains how healthcare organizations can securely harness data for improved outcomes. The conversation dives into the “cloud repatriation” trend—why hospitals are moving critical workloads from public to private environments—and the role of automation and platform design in combating burnout and inefficiency across IT and clinical operations. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In 1975 workers at Life Science Products, a small makeshift pesticide factory in Hopewell, Virginia, became ill after exposure to Kepone, the brand name for the pesticide chlordecone. They made the poison under contract for a much larger Hopewell company, Allied Chemical. Life Science workers had been breathing in the dust for more than a year. Ingestion of the chemical made their bodies seize and shake. News of ill workers eventually led to the discovery of widespread environmental contamination of the nearby James River and the landscape of the small, working-class city. Not only had Life Science dumped the chemical, but so had Allied when the company manufactured it in the 1960s and early 1970s. The resulting toxic impact was not only on the city of Hopewell but also on the faraway fields where Kepone was used as an insecticide.Aspects of this environmental tragedy are all too common: corporate avarice, ignorance, and regulatory failure combined with race and geography to determine toxicity and shape the response. But the Kepone story also contains some surprising medical, legal, and political moments amid the disaster. With Poison Powder: The Kepone Disaster in Virginia and Its Legacy (U Georgia Press, 2023) Gregory S. Wilson explores the conditions that put the Kepone factory and the workers there in the first place and the effects of the poison on the people and natural world long after 1975. Although the manufacture and use of Kepone is now banned by the Environmental Protection Agency, organochlorines have long half-lives, and these toxic compounds and their residues still remain in the environment. Matthew Powell is a doctoral student studying history at the University of Georgia. He focuses on the intersection of environmental and labor history, looking at how workers understand the natural world around them. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/environmental-studies

On March 20th, 1995, the Tokyo subway system was flooded with sarin nerve gas in a coordinated terrorist attack by the religious cult Aum Shinrikyō. Led by the charismatic new-age guru, Shoko Asahara, the well-funded and technologically ambitious Aum organization manufactured and deployed chemical weapons in an attempt to bring about the end of the world. In the chaos that followed, 13 people were killed, thousands were injured, and the international community shuddered at the possibility of future attacks by fringe political groups.    SOURCES: Amarasingam, A. (2017, April 5). A history of sarin as a weapon. The Atlantic.  Cotton, Simon. “Nerve Agents: What Are They and How Do They Work?” American Scientist, vol. 106, no. 3, 2018, pp. 138–40.  Danzig, Richard; Sageman, Marc; Leighton, Terrance; Hough, Lloyd; Yuki, Hidemi; Kotani, Rui; Hosford, Zachary M.. Aum Shinrikyo: Insights Into How Terrorists Develop Biological and Chemical Weapons . Center for a New American Security. 2011. Gunaratna, Rohan. “Aum Shinrikyo's Rise, Fall and Revival.” Counter Terrorist Trends and Analyses, vol. 10, no. 8, 2018, pp. 1–6.  Harmon, Christopher C. “How Terrorist Groups End: Studies of the Twentieth Century.” Strategic Studies Quarterly, vol. 4, no. 3, 2010, pp. 43–84. JSTOR, http://www.jstor.org/stable/26269787.  “IHT: A Safe and Sure System — Until Now.” The New York Times, 21 Mar. 1995. Jones, Seth G., and Martin C. Libicki. “Policing and Japan's Aum Shinrikyo.” How Terrorist Groups End: Lessons for Countering al Qa'ida, RAND Corporation, 2008, pp. 45–62.  Kaplan, David E. (1996) “Aum's Shoko Asahara and the Cult at the End of the World”. WIRED.  Lifton, Robert Jay. Destroying the World to Save It: Aum Shinrikyo, Apocalyptic Violence, and the New Global Terrorism. 1999. Murakami, Haruki. Underground: The Tokyo Gas Attack and the Japanese Psyche. Translated by Alfred Birnbaum and Philip Gabriel. 2001. Murphy, P. (2014, June 21). Matsumoto: Aum's sarin guinea pig. The Japan Times.  Reader, Ian. Religious Violence in Contemporary Japan: The Case of Aum Shinrikyo.  2000. Tucker, Jonathan B. “Chemical/Biological Terrorism: Coping with a New Threat.” Politics and the Life Sciences, vol. 15, no. 2, 1996, pp. 167–83.  Ushiyama, Rin. “Shock and Anger: Societal Responses to the Tokyo Subway Attack.” Aum Shinrikyō and Religious Terrorism in Japanese Collective Memory., The British Academy, 2023, pp. 52–80.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Tiny Show and Tell Us, we read an email from a listener who, as a kid, shared a fun fact with her classroom: polar bears have black skin. Her teacher not only told her she was wrong but embarrassed her in front of the other students. Well, it's time to set the record straight. Polar bears do, in fact, have black skin and we do, in fact, love a grudge and are so glad to provide vindication. Then we talk about the hidden world of insect vibrational communication.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Innovation is moving faster than the law, and investors are racing to keep up. In this episode, Brian Bewley, a partner in the Life Sciences and Health Industry group at Reed Smith, discusses how rapid technological advancements are reshaping healthcare and the life sciences faster than current regulations can keep pace. He explains how shifting federal policies, tariff disruptions, and turnover at key agencies, such as the FDA and HHS, have created uncertainty for investors. Brian also discusses how state-level laws are making it harder for private equity to fund healthcare innovation, and why that could slow progress. Still, he sees growing optimism as investors engage policymakers and prepare for a stronger market in 2026. Tune in to learn how legal, regulatory, and investment forces are converging to shape the future of healthcare innovation! Resources Connect with and follow Brian Bewley on LinkedIn, or reach out via email. Follow Reed Smith LLP on LinkedIn and visit their website.

Season 4, Episode 12: Jack Stone and Alex Gornik sit down with Jon Schultz, Co-Founder and Managing Principal of Onyx Equities, one of the Northeast's most active private real estate firms. Schultz—known for turning around complex office, industrial, and retail assets—shares how Onyx repositions properties, adapts across cycles, and captures value in a rapidly evolving market. From life sciences and medical office to AI-driven data centers, he breaks down the trends reshaping the tri-state region, the lessons learned from decades of leadership, and why success now depends on being “customer-obsessed. TOPICS 00:00 – Introduction 02:10 – Early Career and Founding Onyx Equities 06:15 – Navigating Market Cycles and Value Creation 09:30 – Office Market Shifts and Tenant Demand 12:45 – Life Sciences and Medical Office Expansion 17:40 – Inside the Data Center Gold Rush 22:15 – Rates, Debt, and Opportunities Ahead 27:48 – Tri-State vs. Sun Belt Market Dynamics 34:05 – Leadership, Adaptability, and Lessons Learned 42:30 – Building a Brand Tenants Trust Shoutout to our sponsor, Lev. The AI-powered way to get real estate deals financed. For more episodes of No Cap by CRE Daily visit https://www.credaily.com/podcast/ Watch this episode on YouTube: https://www.youtube.com/@NoCapCREDaily About No Cap Podcast Commercial real estate is a $20 trillion industry and a force that shapes America's economic fabric and culture. No Cap by CRE Daily is the commercial real estate podcast that gives you an unfiltered ”No Cap” look into the industry's biggest trends and the money game behind them. Each week co-hosts Jack Stone and Alex Gornik break down the latest headlines with some of the most influential and entertaining figures in commercial real estate. About CRE Daily  CRE Daily is a digital media company covering the business of commercial real estate. Our mission is to empower professionals with the knowledge they need to make smarter decisions and do more business. We do this through our flagship newsletter (CRE Daily) which is read by 65,000+ investors, developers, brokers, and business leaders across the country. Our smart brevity format combined with need-to-know trends has made us one of the fastest growing media brands in commercial real estate.

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Have you ever wondered why your dog takes such a long time to sniff a patch of grass? Or why flies buzz around so sporadically? It’s because most of what a creature actually senses is invisible to us. They perceive their world as differently as we perceive our own. Pulitzer Prize winning science writer Ed Yong wrote a book about this called An Immense World: How Animal Senses Reveal the Hidden Realms Around Us. Join me for a fun conversation with Ed about the astonishing ways animals sense the world around us. From birds that navigate the open ocean by smell, to penguins that sense vibrations underground. By learning how animals perceive their world, it just might change the way we perceive them, and make us look at our own world a little differently. Check out our episode about AI and Animal Communication: Digital Dr. Dolittle: decoding animal conversations with artificial intelligence. Enjoy BONUS CONTENT and help us continue to create this special immersive storytelling by joining THE WILD Patreon community at www.patreon.com/chrismorganwildlife and you can donate to KUOW at kuow.org/donate/thewild. Thank you. Follow us on Instagram @chrismorganwildlife and @thewildpod for more adventures and behind the scenes action! THE WILD is a production of KUOW in Seattle in partnership with Chris Morgan Wildlife and Wildlife Media. It is produced by Matt Martin and Lucy Soucek, and edited by Jim Gates. It is hosted, produced and written by Chris Morgan. Fact checking by Apryle Craig. Our theme music is by Michael Parker.See omnystudio.com/listener for privacy information.